Lawrence D Mayer

This inventor holds 31 USPTO granted patents and 14 published patent applications, plus 15 CIPO patents and 8 EPO patents, primarily in Drug Delivery Systems. Top assignees: Celator Pharmaceuticals, Inc., The Liposome Company, Inc., Inex Pharmaceuticals Corporation. Active years: 1990-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lawrence D Mayer. Retrieved from https://idiyas.com/inventor/lawrence-d-mayer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 14)

% Patents Active = 93.5

CIPO Patents = 15 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 4.3

ph-index = 20

Forward Citations = 2,092(Granted Patents)

Location History:

Princeton, NJ (US) (2013)
Vancouver, CA (1990 - 2023)

Company Filing History:

17 out of 25

Celator Pharmaceuticals, Inc.

patents

8 out of 115

The Liposome Company, Inc.

patents

4 out of 28

Inex Pharmaceuticals Corporation

patents

4. 3 out of 963

The University of British Columbia

patents

5. 2 out of 525

Oregon Health & Science University

where one patent can have more than one assignee

Years Active: 1990-2023

Loading Chart...

Areas of Expertise:

Nanoparticle Delivery

Liposomal Formulations

Drug Combinations

Cancer Treatment

Sphingosomes

Active Agent Release

Hematopoietic Cancers

High Drug-Lipid Formulations

Encapsulation Techniques

Taxane Delivery

Aminoglycoside Phosphates

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11746386 - Assays and methods for selecting a treatment regimen for a subject with leukemia (2023-09-05),

2. 11413253 - Nanoparticle delivery systems (2022-08-16),

3. 10927418 - Assays and methods for selecting a treatment regimen for a subject with leukemia (2021-02-23),

4. 10905775 - Particulate constructs for release of active agents (2021-02-02),

5. 10835492 - Method of lyophilizing liposomes (2020-11-17),

6. 10722464 - Compositions for delivery of drug combinations (2020-07-28),

7. 10285951 - Nanoparticle delivery systems (2019-05-14),

8. 10166184 - Method of lyophilizing liposomes (2019-01-01),

9. 10058507 - Compositions for delivery of drug combinations (2018-08-28),

10. 10028912 - Method of lyophilizing liposomes (2018-07-24),

11. 8518437 - Lipid carrier compositions with enhanced blood stability (2013-08-27),

12. 8486924 - Taxane delivery system (2013-07-16),

13. 8431806 - Liposomal formulations of anthracycline agents and cytidine analogs (2013-04-30),

14. 8092828 - Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders (2012-01-10),

15. 8022279 - Liposomal formulations of anthracycline agents and cytidine analogs (2011-09-20),

Title: The Innovative Journey of Lawrence D Mayer in Cancer Treatment Solutions

Introduction: Lawrence D Mayer is a prominent inventor based in Vancouver, CA, with an impressive portfolio of 31 patents. His work primarily focuses on innovative solutions for cancer treatment, showcasing his expertise in biotechnology and pharmaceuticals.

Latest Patents: Among his latest patents, Mayer has developed significant advancements such as "Assays and Methods for Selecting a Treatment Regimen for a Subject with Leukemia." This diagnostic method involves genetic and ex vivo testing to identify cancer-bearing subjects suitable for treatment with CPX-351. Notably, his patent emphasizes the effectiveness of combination treatments that improve both the uptake and reduce the toxicity of CPX-351 when paired with FLT-3 inhibitors. Additionally, Mayer has contributed to the field through his patent on "Nanoparticle Delivery Systems," which involve compositions of prodrugs that enhance therapeutic effects compared to conventional free forms of these agents.

Career Highlights: Lawrence D Mayer has built a distinguished career by working with leading companies in the pharmaceutical industry, including Celator Pharmaceuticals, Inc. and The Liposome Company, Inc. His efforts in these organizations have significantly advanced cancer treatment methodologies and drug delivery systems.

Collaborations: Mayer has collaborated with esteemed colleagues, including Marcel B Bally and Paul Tardi. Their collaborative efforts have fostered innovative research and development, further enhancing the effectiveness of cancer therapies.

Conclusion: Lawrence D Mayer's extensive contributions to cancer treatment and drug delivery are commendable. His innovative patents and collaborations exemplify a commitment to improving patient outcomes, making him a notable figure in the field of medical inventions.

Profile summary based on public USPTO records.